1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
PhaseRx, Inc.

PhaseRx, Inc.

PZRXQ
PhaseRx, Inc.US flagOther OTC
0.00
USD
- -
- -
1,169.00Market Cap
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
0.2
0.05
- -
- -
Basic EPS, GAAP
-1.16
-0.94
-2.68
-1.19
Free Cash Flow per Basic Share
-0.83
-0.77
-1.33
-1.1
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-7.12
-6.26
-9.23
-6.84
Tangible Book Value per Share
-7.05
-6.2
1.24
-0.03
Basic Weighted Avg Shares
6
8
8
12
Sales/Revenue/Turnover
1
- -
- -
- -
Operating Margin (%)
-465.92
-1,548.53
- -
- -
Depreciation Expense
1
- -
- -
- -
Net Income, GAAP
-7
-7
-20
-14
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-570.75
-1,967.2
- -
- -
Working Capital
-14
-20
14
3
LT Debt
- -
- -
5
4
Total Equity
-42
-49
9
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
ST Debt
1
2
2
LT Borrowings
5
4
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
16
11
10

Working Capital

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
Total Current Assets
13
9
6
Cash, Cash Equivalents & STI
12
8
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
3
Payables & Accruals
2
1
1
ST Debt
1
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-119.02%
Free Cash Flow
- -
- -
63.8%
Net Income, GAAP
- -
- -
172.97%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
-0.23
-0.22
-0.25
- -
-0.94
2016
-0.2
-1.84
-0.29
-0.3
-2.68
2017
-0.35
-0.3
-0.24
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert W. Overell
Full Time Employees
10
Sector
Healthcare
Industry
Biotechnology
Address
410 West Harrison Street Seattle WA United States of America 98119
IPO Date
May 18, 2016
Website
phaserx.com
Similar Companies
WPD Pharmaceuticals Inc. (WPDPF)
Evogene Ltd. (EVGN)
Poolbeg Pharma PLC (POLBF)
Impact BioMedical Inc. (IBO)
Transcenta Holding Limited (6628.HK)
Acacia Pharma Group plc (ACPH.BR)
Business
PhaseRx, Inc. (PZRXQ) operates as a biopharmaceutical company focused on developing mRNA-based therapies for inherited liver enzyme deficiencies, particularly urea cycle disorders in children; its pipeline includes PRX-OTC for ornithine transcarbamylase deficiency, PRX-ASL for argininosuccinate lyase deficiency, and PRX-ASS1 for argininosuccinate synthetase deficiency, leveraging proprietary Hybrid mRNA technology for intracellular enzyme replacement therapy. The company targets rare genetic diseases causing hyperammonemia and related neurological risks, with programs aimed at reinstating urea cycle function as an alternative to liver transplants. Founded in 2006 and headquartered in Seattle, Washington, PhaseRx serves pediatric patients globally through its research-stage operations. In December 2017, PhaseRx filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, listing approximately $4.1 million in assets and $5.6 million in liabilities, amid cash constraints and Nasdaq delisting risks; the filing enabled exploration of strategic alternatives including asset sales. In February 2018, its assets were approved for sale to Roivant Sciences GmbH for $800,000 in cash plus debt assumption, though the deal was later cancelled in January 2019, leaving the company in a wind-down status with no active operations or recent developments reported as of 2025.